Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Get Free Report) CAO Carrie Liao sold 2,347 shares of the business's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total transaction of $15,818.78. Following the transaction, the chief accounting officer now owns 144,923 shares in the company, valued at $976,781.02. This represents a 1.59 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Carrie Liao also recently made the following trade(s):
- On Thursday, December 26th, Carrie Liao sold 2,273 shares of Mind Medicine (MindMed) stock. The stock was sold at an average price of $7.43, for a total transaction of $16,888.39.
Mind Medicine (MindMed) Stock Down 3.7 %
MNMD traded down $0.24 during trading on Friday, hitting $6.19. 1,096,667 shares of the company's stock traded hands, compared to its average volume of 1,426,184. The stock has a market capitalization of $466.53 million, a price-to-earnings ratio of -2.74 and a beta of 2.57. The company's 50 day simple moving average is $7.26 and its two-hundred day simple moving average is $6.97. Mind Medicine has a 12-month low of $5.03 and a 12-month high of $12.22. The company has a current ratio of 9.00, a quick ratio of 9.00 and a debt-to-equity ratio of 0.09.
Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.08). During the same quarter in the prior year, the firm earned ($0.59) earnings per share. Analysts predict that Mind Medicine will post -1.35 earnings per share for the current fiscal year.
Institutional Trading of Mind Medicine (MindMed)
A number of large investors have recently made changes to their positions in MNMD. Barclays PLC lifted its position in Mind Medicine (MindMed) by 203.6% during the third quarter. Barclays PLC now owns 136,098 shares of the company's stock valued at $775,000 after purchasing an additional 91,271 shares during the period. Wellington Management Group LLP raised its stake in Mind Medicine (MindMed) by 142.6% during the 3rd quarter. Wellington Management Group LLP now owns 185,722 shares of the company's stock valued at $1,057,000 after buying an additional 109,152 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Mind Medicine (MindMed) by 10.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,677,702 shares of the company's stock worth $9,548,000 after buying an additional 162,933 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Mind Medicine (MindMed) by 48.8% in the 4th quarter. SG Americas Securities LLC now owns 24,406 shares of the company's stock worth $170,000 after buying an additional 8,004 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of Mind Medicine (MindMed) by 0.5% in the third quarter. State Street Corp now owns 1,814,829 shares of the company's stock worth $10,326,000 after acquiring an additional 9,782 shares during the period. 27.91% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on MNMD shares. Evercore ISI began coverage on Mind Medicine (MindMed) in a research report on Tuesday, January 28th. They issued an "outperform" rating and a $23.00 target price for the company. Robert W. Baird lowered their price objective on Mind Medicine (MindMed) from $27.00 to $16.00 and set an "outperform" rating for the company in a research report on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 target price on shares of Mind Medicine (MindMed) in a research report on Friday, March 7th. Chardan Capital initiated coverage on shares of Mind Medicine (MindMed) in a research report on Friday, December 20th. They set a "buy" rating and a $20.00 price target for the company. Finally, Oppenheimer restated an "outperform" rating and issued a $20.00 price objective on shares of Mind Medicine (MindMed) in a report on Tuesday, December 17th. Ten equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $25.11.
Read Our Latest Stock Report on Mind Medicine (MindMed)
About Mind Medicine (MindMed)
(
Get Free Report)
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Further Reading
Before you consider Mind Medicine (MindMed), you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mind Medicine (MindMed) wasn't on the list.
While Mind Medicine (MindMed) currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn how options trading can help you navigate market volatility, manage risk, and maximize returns with MarketBeat's "Unlock the Potential in Options Trading." Click the link below to have this special report delivered to your inbox.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
